Latest Conference Articles

June 17th 2017, 8:54pm

International Conference on Malignant Lymphoma

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

June 17th 2017, 12:45am

International Conference on Malignant Lymphoma

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

June 16th 2017, 10:39pm

International Conference on Malignant Lymphoma

BGB-3111, a highly specific BTK inhibitor, is active in patients with Waldenström macroglobulinemia, according to an interim analysis from an ongoing phase I trial.

June 16th 2017, 9:08pm

International Conference on Malignant Lymphoma

Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.

June 16th 2017, 6:29pm

International Conference on Malignant Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

June 16th 2017, 6:17pm

International Conference on Malignant Lymphoma

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

June 16th 2017, 1:06am

International Conference on Malignant Lymphoma

Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced EZH2-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.

June 15th 2017, 10:39pm

International Conference on Malignant Lymphoma

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

June 15th 2017, 7:35pm

International Conference on Malignant Lymphoma

Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.

June 15th 2017, 6:21pm

International Conference on Malignant Lymphoma

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

June 15th 2017, 6:08pm

International Conference on Malignant Lymphoma

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.

June 15th 2017, 12:30am

International Conference on Malignant Lymphoma

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

June 15th 2017, 12:10am

International Conference on Malignant Lymphoma

Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.

June 14th 2017, 11:59pm

International Conference on Malignant Lymphoma

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

June 14th 2017, 6:53pm

International Conference on Malignant Lymphoma

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

June 14th 2017, 6:51pm

International Conference on Malignant Lymphoma

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

June 9th 2017, 8:32pm

ASCO Annual Meeting

In recognition of the potential for real-world evidence to significantly improve the way patients with cancer are treated, CancerLinQ has formed new partnerships with the US government that are expected to coordinate the sharing of patient data and incorporate that information into the FDA regulatory process.

June 9th 2017, 7:19pm

ASCO Annual Meeting

Patients with T790M-positive non–small cell lung cancer had superior outcomes when treated with osimertinib (Tagrisso) for central nervous system metastases, according to phase III results presented at the 2017 ASCO Annual Meeting.

June 9th 2017, 6:59pm

ASCO Annual Meeting

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses findings from a phase Ib/II dose-escalation study evaluating the triple combination therapy with encorafenib, binimetinib, and ribociclib (Kisqali) in patients with BRAF V600-mutant solid tumors and melanoma.

June 7th 2017, 12:41am

ASCO Annual Meeting

Combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) as a frontline regimen induced a response rate of 58.2% in patients with advanced renal cell carcinoma, according to findings from the phase Ib JAVELIN Renal 100 trial presented at the 2017 ASCO Annual Meeting.